What Is the Life Expectancy for MAC Lung Infection?

Most people diagnosed with Mycobacterium avium complex (MAC) lung disease live for many years, but the range is wide. A systematic review pooling data from multiple studies found a five-year all-cause mortality of about 27 percent, though individual study estimates ranged from 10 to 48 percent depending on the patient population studied.

What the Five-Year Survival Numbers Actually Show

The most comprehensive look at survival comes from a systematic review that combined results across several research cohorts. The pooled five-year all-cause mortality was roughly 27 percent, meaning about three out of four patients were still alive five years after diagnosis.¹ That number, however, masks enormous variation. Some cohorts reported five-year mortality as low as 10 percent, while others were as high as 48 percent. The studies that included more patients with cavitary disease or multiple other health conditions reported the worst outcomes, while Asian cohorts tended to show lower mortality.

One Japanese study that followed patients for longer reported a median time to death from any cause of roughly 23 years in the group receiving standard multidrug therapy, and about 21 years in those initially observed without treatment.² Those are strikingly long survival times, and they underscore a point that gets lost in the scarier statistics: many people with MAC lung disease die with the disease rather than from it.

MAC as the Actual Cause of Death Is Rarer Than You Might Think

One of the most reassuring findings in MAC lung disease research is the gap between all-cause mortality and deaths directly attributable to the infection itself. A large retrospective study of 782 patients with nodular bronchiectatic MAC lung disease found that while all-cause mortality at ten years was about 27 percent, only 2.4 percent of patients actually died from progression of their MAC disease.³ The vast majority of deaths were from other causes, including heart disease, other cancers, and general decline associated with aging.

This distinction matters because MAC lung disease disproportionately affects older adults who already carry other health burdens. When a study reports that a quarter of MAC patients died within a certain period, it is easy to assume the infection itself did the damage. In many cases, particularly with the slower-progressing nodular bronchiectatic form of the disease, the infection contributes to reduced lung function and quality of life but is not what ultimately proves fatal.

What Pushes Survival in One Direction or the Other

Several factors consistently predict worse outcomes across studies. The strongest and most reproducible include:

Cavitary disease: Patients whose imaging shows cavities in the lungs fare significantly worse than those with the nodular bronchiectatic pattern. In one study, cavities roughly tripled the risk of death.⁴
Emphysema or COPD: Coexisting emphysema was associated with dramatically higher mortality in that same study, with a hazard ratio over 11.⁴
Low body weight: A body mass index under 18.5 carried more than four times the risk of death.
Male sex: Men consistently do worse across multiple study populations.
Advanced age: Patients over 65 face higher mortality, though this is partly confounded by the fact that older patients also carry more comorbidities.

A multicentre study developed a prognostic scoring model that assigned points for five independent risk factors: age 65 or older, male sex, interstitial pneumonia, low blood albumin (below 3.5 g/dL), and cavitary lesions 2 centimeters or larger. Of these, low albumin had the strongest association with death from respiratory infection, carrying nearly nine times the risk.⁵ That scoring system performed well in predicting who would do poorly, suggesting that a few routine lab values and imaging findings can give clinicians a reasonable sense of prognosis early on.

Why Body Weight and Nutrition Matter So Much

Low body weight keeps showing up as one of the strongest predictors of poor outcomes in MAC lung disease, and it works through multiple channels. Underweight patients are more likely to have treatment failure: one study found that nearly half of patients with low BMI failed to achieve sputum culture conversion, compared to about a quarter of those with preserved body weight.⁶ Patients with MAC lung disease also tend to have lower visceral fat and lower overall nutrient intake than healthy controls, suggesting the disease itself may contribute to wasting.⁷

A related measure, the Prognostic Nutritional Index (which combines albumin levels and lymphocyte counts into a single score), has also been studied. Patients classified as malnourished at the time of diagnosis had roughly 2.8 times the risk of death from any cause, and were about 2.6 times more likely to be unable to tolerate treatment.⁸ This creates a feedback loop: malnourished patients tolerate drugs poorly, so they get suboptimal treatment, which allows the disease to progress, which further erodes their nutritional status.

For patients and caregivers, the practical takeaway is that maintaining weight and nutrition is not just a wellness goal but something that may meaningfully affect how long and how well you live with MAC. This is one of the few modifiable factors in the equation.

What Happens When MAC Is Left Untreated

Not every patient receives treatment right away. Some have mild disease that clinicians choose to monitor, and others are too frail or unwilling to commit to the lengthy antibiotic regimen. A study of initially untreated patients found that the four-year mortality rate was high, and that certain imaging findings at diagnosis, such as consolidation patterns and higher radiographic scores, predicted who would deteriorate most.⁹ Radiographic deterioration during the observation period and never starting treatment were also risk factors for death within four years.

The evidence on whether starting multidrug therapy promptly changes overall survival is actually less clear-cut than you might expect. The study comparing treated and observed cohorts found that the difference in total mortality rates between the groups was not statistically significant, with median survival times of roughly 23 and 21 years respectively.² This does not mean treatment is pointless. Treatment aims to reduce bacterial burden, slow lung damage, improve symptoms, and prevent progression to cavitary disease. But it does mean that the decision to treat involves weighing real drug toxicity against a disease that, in some patients, progresses slowly enough that observation can be reasonable.

How Treatment Works and Why It Is Difficult to Complete

Standard treatment for MAC lung disease is a three-drug regimen built around a macrolide antibiotic (either clarithromycin or azithromycin) combined with rifampin and ethambutol. Current guidelines recommend continuing this combination for at least 12 months after sputum cultures convert to negative, which typically means a total treatment duration of 18 months or longer.¹⁰ Even under the best circumstances, rates of default (patients stopping treatment early) and disease recurrence after completing treatment remain stubbornly high.

One major reason for those high default rates is drug side effects. Adverse drug reactions are a serious and common barrier to completing MAC therapy, frequently forcing clinicians to modify regimens, switch to less effective alternatives, or stop treatment entirely.¹¹ Gastrointestinal symptoms, liver toxicity, vision changes from ethambutol, and drug interactions with rifampin are all well-known hazards. For older and frailer patients, these side effects can be harder to manage. This is the uncomfortable reality of MAC treatment: the regimen that works best is also one that many patients struggle to finish.

When the Standard Drugs Stop Working

Macrolide resistance represents one of the most serious complications in MAC lung disease. When the bacteria become resistant to clarithromycin or azithromycin, the backbone of the standard regimen is effectively neutralized. A systematic review of macrolide-resistant MAC found that the pooled sputum culture conversion rate after alternative antibiotic combinations or surgical resection was only about 21 percent, and the one-year all-cause mortality was roughly 10 percent.¹² Compare that to the much more favorable outcomes in macrolide-susceptible disease, and the stakes of preserving macrolide sensitivity become obvious.

For refractory cases, newer options have emerged. Amikacin liposome inhalation suspension (ALIS), an inhaled antibiotic that delivers the drug directly to the lungs, was studied in an open-label extension trial for patients who had failed prior treatment. By 12 months of combined ALIS and guideline-based therapy, about a third of newly treated patients achieved sputum culture conversion.¹³ That conversion rate is modest, but for patients who have run out of standard options, any additional tool matters. Surgical removal of a localized area of diseased lung is also sometimes considered, though it applies only to a carefully selected subset of patients.

Recurrence After Apparently Successful Treatment

Even after completing a full course of treatment and achieving negative sputum cultures, MAC lung disease can come back. Research on recurrence has revealed an important distinction: about half of recurrences are true relapses (the original strain was never fully eradicated), while roughly half are reinfections with a new strain acquired from the environment.¹⁴ Relapses tend to occur sooner, with a median of about 7 months after finishing therapy, while reinfections show up later, at a median of roughly 22 months. Relapses are also more likely to show increased macrolide resistance, which makes the second course of treatment harder.

The reinfection finding is sobering because it means that even a perfectly successful treatment course does not protect you from getting MAC again. The bacteria are ubiquitous in soil and water, and whatever structural or immunological features of your lungs made you susceptible the first time are still present after treatment. This is one reason why MAC lung disease is sometimes described as a chronic condition to be managed rather than a one-time infection to be cured.

Disseminated MAC in Immunocompromised Patients

The survival picture changes dramatically when MAC spreads beyond the lungs, which happens almost exclusively in people with severely compromised immune systems, particularly those with advanced HIV/AIDS. A study tracking disseminated MAC (DMAC) cases from 1992 to 2015 found that patients who never started combination antiretroviral therapy had a median survival of just 189 days. Among those who did receive antiretroviral treatment, the picture improved substantially, with 25 percent still alive at five years and 7 percent alive at ten years after DMAC diagnosis.¹⁵

Even with antiretroviral therapy, though, mortality was vastly elevated compared to the general population. In the first year after a DMAC diagnosis, patients on antiretrovirals had a standardized mortality ratio of 69, meaning they were dying at roughly 69 times the expected rate. That ratio dropped steeply over subsequent years but remained nearly seven times the expected rate even five years out.¹⁵ Disseminated MAC in the context of HIV is a fundamentally different disease from pulmonary MAC in an otherwise healthy person, and the two should not be confused when thinking about prognosis.

The Species Within MAC Can Behave Differently

MAC is not a single organism but a complex of related species, primarily Mycobacterium avium and Mycobacterium intracellulare, along with several others. A prospective study tracking adults with speciated MAC lung disease found that the specific species involved, and whether that species persisted over time, contributed to distinct clinical phenotypes with varying severity and progression.¹⁶ In the prognostic scoring work mentioned earlier, infection with M. intracellulare was associated with increased mortality risk in initial analyses, though it did not survive as an independent predictor in the final model.⁵

This is an area where the science is still catching up with clinical reality. Many older studies lumped all MAC species together, which may have obscured meaningful differences in virulence and treatment response. As speciation becomes more routine in clinical labs, we may find that the prognosis for M. avium lung disease differs appreciably from M. intracellulare, and that treatment strategies need to account for which organism is actually causing the problem.

Living With MAC Beyond the Survival Statistics

Survival numbers only tell part of the story. A cross-sectional study of 235 patients with MAC lung disease found that their health-related quality of life was significantly worse than population norms on nearly every dimension measured, including physical functioning, energy levels, social functioning, and the ability to carry out daily roles.¹⁷ The two areas where patients scored within normal range were bodily pain and mental health, which suggests that the burden of MAC is less about acute suffering and more about a slow erosion of physical capacity and social engagement.

Factors that predicted the worst quality-of-life scores included being on active treatment (likely reflecting both disease severity and drug side effects), having a positive sputum culture within the past year, higher levels of systemic inflammation, and older age.¹⁷ For patients weighing whether to start or continue treatment, this is a legitimate consideration: the goal of therapy is not just to extend life but to preserve the ability to participate in it. When treatment itself degrades quality of life through side effects while the disease progresses slowly, the calculus becomes genuinely difficult, and there is no single right answer that applies to everyone.